Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Personalizing non-small cell lung cancer treatment through patient-derived xenograft models: preclinical and clinical factors for consideration.
Fuchs V, Sobarzo A, Msamra M, Kezerle Y, Linde L, Sevillya G, Anoze A, Refaely Y, Cohen AY, Melamed I, Azriel A, Shoukrun R, Raviv Y, Porgador A, Peled N, Roisman LC. Fuchs V, et al. Among authors: roisman lc. Clin Transl Oncol. 2024 Mar 29. doi: 10.1007/s12094-024-03450-3. Online ahead of print. Clin Transl Oncol. 2024. PMID: 38553659
The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy.
Prelaj A, Ganzinelli M, Trovo' F, Roisman LC, Pedrocchi ALG, Kosta S, Restelli M, Ambrosini E, Broggini M, Pravettoni G, Monzani D, Nuara A, Amat R, Spathas N, Willis M, Pearson A, Dolezal J, Mazzeo L, Sangaletti S, Correa AM, Aguaron A, Watermann I, Popa C, Raimondi G, Triulzi T, Steurer S, Lo Russo G, Linardou H, Peled N, Felip E, Reck M, Garassino MC. Prelaj A, et al. Among authors: roisman lc. Clin Lung Cancer. 2023 Jun;24(4):381-387. doi: 10.1016/j.cllc.2023.02.005. Epub 2023 Feb 28. Clin Lung Cancer. 2023. PMID: 36959048
Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study.
Peled N, Roisman LC, Levison E, Dudnik J, Chernomordikov E, Heching N, Dudnik E, Keren-Rosenberg S, Nechushtan H, Salhab A, Hershkovitz D, Tsuriel S, Hannes V, Rotem O, Lazarev I, Lichtenberg R, Granot IS, Krayim B, Shalata W, Levin D, Krutman Y, Allen AM, Blumenfeld P, Lavrenkov K, Kian W. Peled N, et al. Among authors: roisman lc. Int J Radiat Oncol Biol Phys. 2023 Sep 1;117(1):105-114. doi: 10.1016/j.ijrobp.2023.03.042. Epub 2023 Mar 15. Int J Radiat Oncol Biol Phys. 2023. PMID: 36925073 Clinical Trial.
Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer.
Kian W, Christopoulos P, Remilah AA, Levison E, Dudnik E, Shalata W, Krayim B, Marei R, Yakobson A, Faehling M, Kahala D, Sara Granot I, Levitas D, Peled N, Roisman LC. Kian W, et al. Among authors: roisman lc. Front Oncol. 2022 Sep 20;12:1010311. doi: 10.3389/fonc.2022.1010311. eCollection 2022. Front Oncol. 2022. PMID: 36203432 Free PMC article.
77 results